(Press-News.org) PASADENA, Calif. — A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age. The study was published March 15, 2023, in Lancet ID.
“Among Kaiser Permanente members in Southern California who tested positive for coronavirus infection, receiving Paxlovid within 5 days of the start of COVID-19 symptoms was associated with substantial reductions in the risk of hospital admission or death,” said Sara Tartof, PhD, the senior author of the study and an epidemiologist with the Kaiser Permanente Southern California Department of Research & Evaluation. “These findings are even more notable because in this population with high levels of vaccination, we still see additional benefits of this treatment.”
Paxlovid is an oral therapeutic drug aimed at reducing the risk for severe outcomes of coronavirus infection. It is manufactured by Pfizer Inc. It currently has emergency use authorization by the U.S. Food and Drug Administration for adults and children 12 and older who are at high risk for progression to severe COVID-19.
The study analyses included patients with positive results from coronavirus tests undertaken in outpatient settings between April 8 and October 7, 2022. In the study population, 7,274 people had received Paxlovid, and 126,152 had not received Paxlovid. It was a time dominated by the omicron subvariants BA.2, BA.4, and BA.5. Overall, 86% of the 133,426 participants had received 2 COVID-19 vaccine doses, and 61% had received 3 or more.
The study found:
Effectiveness in preventing hospital admission or death within 30 days after a positive test was 80% for people who were dispensed Paxlovid within 5 days after symptom onset.
Within the subgroup of patients who were dispensed Paxlovid on the day of their positive COVID-19 test, effectiveness was 90%.
Effectiveness declined to 44% for patients who received Paxlovid 6 or more days after symptom onset or for cases not experiencing acute clinical symptoms.
Overall, for patients who received Paxlovid at any time within their clinical course, effectiveness was 54%.
Effectiveness in preventing intensive care unit admission, mechanical ventilation, or death within 60 days after a positive COVID-19 test was 89% for patients who were dispensed Paxlovid 0 to 5 days after symptom onset, and 84% for people who were dispensed Paxlovid treatment at any time.
“Our data showed that the sooner people take Paxlovid upon symptom onset, the more effective the medication can be,” Tartof said. “However, there is still some benefit to treatment 6 or more days after symptom onset. People should talk with their doctors about the best approach for them.”
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve approximately 12.6 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations clinical research, health education, and the support of community health.
Paxlovid associated with lower risk of hospital admission
A Kaiser Permanente study finds COVID-19 patients treated quickly with Paxlovid have a 90% lower risk of hospitalization and death.
ELSE PRESS RELEASES FROM THIS DATE:
Children at risk of multiple sclerosis often go undetected in early stages
Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight that could delay treatment of the disease at its earliest stages, according to a Rutgers study. Magnetic resonance imaging (MRI) is the primary tool used for diagnosis of MS, and doctors have applied various standards over the years to classify those most likely to develop the disease. The most recent standard, known as the McDonald criteria, was last updated in 2017. In some cases, imaging suspicious for MS is found incidentally ...
Breakthrough in the understanding of quantum turbulence
Researchers have shown how energy disappears in quantum turbulence, paving the way for a better understanding of turbulence in scales ranging from the microscopic to the planetary. Dr Samuli Autti from Lancaster University is one of the authors of a new study of quantum wave turbulence together with researchers at Aalto University. The team’s findings, published in Nature Physics, demonstrate a new understanding of how wave-like motion transfers energy from macroscopic to microscopic length scales, and their results confirm ...
Selwyn Rogers named associate editor of prestigious New England Journal of Medicine
Renowned University of Chicago Medicine trauma surgeon Selwyn O. Rogers Jr., MD, MPH, has been named an associate editor of the New England Journal of Medicine (NEJM), effective March 16. The founding director of the UChicago Medicine Trauma Center, Rogers is a Professor of Surgery at UChicago and Chief of Trauma and Acute Care Surgery at its 1,296-bed academic health system based on Chicago’s South Side. A leading public health expert whose research focuses on the healthcare needs of underserved populations — particularly those impacted by intentional violence — he is the first surgeon in more than a decade to serve as an associate editor at NEJM, ...
Perovskite solar cells from the slot die coater - a step towards industrial production
Metal halide perovskites are considered to be a particularly low-cost and promising class of materials for next-generation solar modules. Perovskite solar cells can be produced with coating processes using liquid inks made from precursor materials and various solvents. After coating, the solvents evaporate and the perovskites crystallise to form a more or less homogeneous layer. Options for upscaling Prof. Dr. Eva Unger's team at Helmholtz-Zentrum Berlin has extensive expertise in solution-based processing methods and is investigating options for upscaling. "Perovskite photovoltaics is the best solution-processable PV technology available," says Eva Unger, ...
Researchers highlight nucleolar DNA damage response in fight against cancer
Cancer, which affects millions every year, requires proteins to spread through the body. In a new strategy to beat the wide-ranging disease, scientists are sabotaging its protein factories. In a new forum paper published in Trends in Biology, researchers from the University of North Carolina at Charlotte encapsulated the young field of nucleolar DNA damage response (DDR) pathways. The review highlights six mechanisms by which cells repair DNA damage, including one which was published five months ago in Nucleic Acids Research by the same authors. By attacking these mechanisms, future applied researchers will be able to ...
Food security: New tool can forecast food insecurity up to 30 days in advance
A new tool that can be used to forecast the prevalence of individuals within a country that may have insufficient access to food — known as food insecurity — up to 30 days into the future is presented in a study published in Scientific Reports. The authors suggest that the tool could aid decision makers in countries at risk of food insecurity and help facilitate more timely responses. Elisa Omodei and colleagues developed the tool using food consumption data from Burkina Faso, Cameroon, Mali, Nigeria, Syria and Yemen — all countries that have recently ...
Study of immune ‘neighborhoods’ highlights macrophages as key players in invasive breast cancers
Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer. Targeting a different type of immune cell called macrophages could be a more effective approach, suggests a comprehensive new analysis of invasive ER+ breast cancers led by University of Pittsburgh School of Medicine scientists. Published today in Nature Cancer, the study found that macrophages were the dominant immune cell infiltrating ER+ invasive lobular carcinoma (ILC) and invasive ductal carcinoma ...
Genetic causes of three previously unexplained rare diseases identified
New York, NY (March 16, 2023) – Using a new computational approach they developed to analyze large genetic datasets from rare disease cohorts, researchers at the Icahn School of Medicine at Mount Sinai and colleagues have discovered previously unknown genetic causes of three rare conditions: primary lymphedema (characterized by tissue swelling), thoracic aortic aneurysm disease, and congenital deafness. The work was done in collaboration with colleagues at the University of Bristol, UK; KU Leuven, Belgium; the University of Tokyo; the University of Maryland; Imperial College London, and others from around the world. An enhanced understanding of the functions ...
NYU Abu Dhabi researchers discover a new approach to harvesting aerial humidity with organic crystals
Fast facts: The global shortage of fresh water currently affects hundreds of millions of people around the world, and it is estimated that by 2025, 1.8 billion people will experience severe water scarcity and hunger due to loss of fertile farming lands caused by droughts. The discovery of alternative water-harvesting technologies holds the potential to alleviate the foreseeable socioeconomic impacts of severe water scarcity. Abu Dhabi, UAE, March 16 2023: Researchers of the Smart Materials Lab (SML) and the Center for Smart Engineering Materials (CSEM) at NYU Abu Dhabi (NYUAD) have reported a novel method of harvesting water from ...
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
HOUSTON ― In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC). New findings from the NEOSTAR trial, published today in Nature Medicine, provide further support for neoadjuvant immunotherapy-based treatment as an approach to reduce viable tumor at surgery and to improve outcomes in NSCLC. The combination also was associated with an increase in immune cell infiltration and a favorable gut microbiome ...
LAST 30 PRESS RELEASES:
Carbon capture method plucks CO2 straight from the air
Dr. Tanya Stoyanova receives Department of Defense award to find new lung cancer treatments
Carol L. Silva elected fellow of the National Academy of Public Administration
Independent physician practices can keep up with larger consolidated practices in a pandemic
Join GSA in Tampa for the Nation’s Premier Aging Conference!
Female animals may learn mate preferences based on what sets other females’ choices apart from the crowd
Despite increasing rates of tuberculosis in prisons across the globe, current WHO TB prevention guidelines fail to reach incarcerated populations
Computer model predicts who needs lung cancer screening
Rural counties showing steeper decline in health measures compared to urban counties in 2015 versus 2019—though all areas showed declines in health measures over time
Interconnected factors increase household food insecurity in Brazil
Real-world study confirms reliability of tool assessing 10-year risk prediction of heart disease
Newly established Bulgarian Barcode of Life to support biodiversity conservation in the country
On-Yee Lo, PhD, receives NAM Healthy Longevity Catalyst Award for work on brain stimulation to improve physical and cognitive functions in older adults
New recommendation on meningitis vaccines for infants in sub-Saharan Africa
Organizing can give tenants power to effect change
The World Mitochondria Society will host Targeting Mitochondria 2023 with challenging visions in Berlin
New strategy for eye condition could replace injections with eyedrops
Aston University engineering graduate launches first AI powered grill
IU cancer researcher receives $2.2 million grant for metastatic breast cancer research
Using recent diagnostic scans can substantially cut time to treatment for patients needing urgent palliation
Brain regions identified that may play a role in Sudden Unexpected Death in Epilepsy
Researchers report protein mutation creates ‘super’ T cells with potential to fight off cancer and infections
Enhancing the efficiency of plant regeneration
Registration now open for Energy Department’s National Science Bowl®
Disaster-proofing sustainable neighborhoods requires thorough long-term planning, new Concordia study shows
Carbon-capture tree plantations threaten tropical biodiversity for little gain, ecologists say
Can science take the STING out of runaway inflammation?
Adherence to CPAP treatment and the risk of recurrent cardiovascular events
Spending on mental health services for kids and adolescents has risen by more than 25% since beginning of pandemic
Surgical scorecards may cut cost of surgical procedures without impacting outcomes[Press-News.org] Paxlovid associated with lower risk of hospital admission
A Kaiser Permanente study finds COVID-19 patients treated quickly with Paxlovid have a 90% lower risk of hospitalization and death.